The health care giant is being probed for two reasons - relationships with psychiatrists regarding an unnamed medication, and relationships with doctors and unspecified organizations concerning its Cypher stents, according to a filing with the Securities and Exchange Commission (see page 30).
On October 16, the US Senate Finance Committee and the Senate Special Committee on Aging sent a letter seeking info about the Cypher stent relationships. And the Finance Committee, separately, sent a letter on October 23 regarding info "on any payments or benefits to a number of specified psychiatrists associated with psychiatric professional associations or otherwise authorities in their field." Which drug may be involved? Well, J&J sells the Risperdal and Invega antipsychotics, although a J&J spokesman says the health care giant has nothing more to say.